Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Merck
AstraZeneca
McKinsey
Harvard Business School
McKesson

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for tepotinib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for tepotinib: Sponsors, patents, clinical trial progress

tepotinib is an investigational drug.

There have been 8 clinical trials for tepotinib. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Liver Diseases. The leading clinical trial sponsors are Merck KGaA, EMD Serono Research & Development Institute, Inc., and Merck KGaA, Darmstadt, Germany.

There are thirteen US patents protecting this investigational drug and one hundred and forty-seven international patents.

Recent Clinical Trials for tepotinib
TitleSponsorPhase
A Study of Tepotinib Plus Osimertinib in Epidermal Growth Factor Receptor (EGFR ) Tyrosine Kinase Inhibitor (TKI) Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC)Merck KGaA, Darmstadt, GermanyPhase 2
A Study of Tepotinib Plus Osimertinib in Epidermal Growth Factor Receptor (EGFR ) Tyrosine Kinase Inhibitor (TKI) Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC)EMD Serono Research & Development Institute, Inc.Phase 2
Bioequivalence of Tablet Formulation 3 (TF3) and Tablet Formulation 2 (TF2) and Effect of Food on the Pharmacokinetics (PK) of TepotinibMerck KGaAPhase 1

See all tepotinib clinical trials

Clinical Trial Summary for tepotinib

Top disease conditions for tepotinib
Top clinical trial sponsors for tepotinib

See all tepotinib clinical trials

US Patents for tepotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
tepotinib   Start Trial Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative MERCK PATENT GMBH (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Pyrimidinyl pyridazinone derivatives Merck Patent Gesellschaft mit beschrankter Haftung (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Pyridazinone derivatives Merck Patent GmbH (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Pyridazinone derivatives MERCK PATENT GmbH (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Pyrimidinyl pyridazinone derivatives Merck Patent GmbH (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo- -1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof MERCK PATENT GmbH (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Pyridazinone derivatives Merck Patent GmbH (Darmstadt, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for tepotinib

Drugname Country Document Number Estimated Expiration Related US Patent
tepotinib Australia 2015360006 2034-12-11   Start Trial
tepotinib Brazil 112017010232 2034-12-11   Start Trial
tepotinib Canada 2970394 2034-12-11   Start Trial
tepotinib Chile 2017001477 2034-12-11   Start Trial
tepotinib China 106999492 2034-12-11   Start Trial
tepotinib European Patent Office 3229796 2034-12-11   Start Trial
tepotinib Israel 252750 2034-12-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKesson
AstraZeneca
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.